person · Reporting owner

RHOADS ANN D

Disclosed activity across 8 companies

Tapewire entity: 34772
SEC CIK: 0001250252

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Evoke Pharma IncEVOK · Entity 71094	Director	May 05, 2021	July 23, 2021
GLOBUS MEDICAL INCGMED · Entity 3496	Director	June 04, 2026	June 08, 2026
IRIDEX CORPIRIX · Entity 7882	Director	June 13, 2018	June 16, 2018
QuidelOrtho CorpQDEL · Entity 4986	Director	June 25, 2026	June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Evoke Pharma Inc

Report date May 05, 2021 · Filed July 23, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2031-05-04	Direct	61,750	Reported balance After 2021-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-05 · Grant · Acquired 61,750 · Balance 61,750 F1: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date.

GLOBUS MEDICAL INC

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	40,384	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Exercise / conversion · Acquired 25,000 · Balance 40,384
Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2027-01-30	Direct	0	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: These options were granted on January 30, 2017 and are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted on January 30, 2017 and are fully vested.

IRIDEX CORP

Report date June 13, 2018 · Filed June 16, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,690	Reported balance After 2018-06-13 transaction · row 1 1 source row Row 1 · 2018-06-13 · Grant · Acquired 5,690 · Balance 5,690 F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 13, 2019 or the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on the earlier of June 13, 2019 or the date of the Issuer's next annual meeting of stockholders.

QuidelOrtho Corp

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	15,532	Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027.
Restricted Stock Units (Converted)SEC Table II · derivative / convertible security	Direct	3,698	Reported balance After 2026-06-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-25 · Grant · Acquired 3,698 · Balance 3,698 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027.
Restricted Stock Units (Premium)SEC Table II · derivative / convertible security	Direct	369	Reported balance After 2026-06-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-25 · Grant · Acquired 369 · Balance 369 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F2: The restricted stock units will vest on June 25, 2027.

F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.

F4: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forty Seven, Inc.

Report date April 07, 2020 · Filed April 07, 2020

Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-04-07 transaction · row 1 1 source row Row 1 · 2020-04-07 · Disposition to issuer · Disposed 37,414 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-11	Direct	Reported balance After 2020-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-07 · Disposition to issuer · Disposed 120,147 · Balance 0 F2: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26	Direct	Reported balance After 2020-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-04-07 · Disposition to issuer · Disposed 74,838 · Balance 0 F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.75 · Expires 2029-12-12	Direct	Reported balance After 2020-04-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-04-07 · Disposition to issuer · Disposed 107,827 · Balance 0 F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2: This option, which provided for vesting over a four-year period as follows: (i) 26,710 shares subject to the option vested on March 29, 2019, and (ii) the balance of the shares subject to the option vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $10,412,851.15, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,491,635.22, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,442,663.25, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

QUIDEL CORP /DE/

Report date May 27, 2022 · Filed June 01, 2022

Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-27 transaction · row 1 1 source row Row 1 · 2022-05-27 · Disposition to issuer · Disposed 2,248 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-27 · Disposition to issuer · Disposed 128 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.

F2: Each restricted stock unit represents the right to receive one share of Quidel common stock.

F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Repare Therapeutics Inc.

Report date January 28, 2026 · Filed January 29, 2026

Section 16 reporting ended · disclosed 2026-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2026-01-28 transaction · row 1 1 source row Row 1 · 2026-01-28 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.

F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

iTeos Therapeutics, Inc.

Report date August 29, 2025 · Filed August 29, 2025

Section 16 reporting ended · disclosed 2025-08-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16	Direct	0	Reported balance After 2025-08-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-08-29 · Disposition to issuer · Disposed 27,178 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option")

F2: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 25, 2026 Filed Jun 29, 2026 21:59 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	369	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000007 · wk-form4_1782770364.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369 Underlying: Common Stock · 369 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document
June 25, 2026 Filed Jun 29, 2026 21:59 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	3,698	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000007 · wk-form4_1782770364.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,698 Underlying: Common Stock · 3,698 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares will vest on December 25, 2026, and 925 shares will vest on March 25, 2027. Read SEC document
June 25, 2026 Filed Jun 29, 2026 21:59 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	15,532	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000007 · wk-form4_1782770364.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,532 Underlying: Common Stock · 15,532 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. Read SEC document
June 04, 2026 Filed Jun 8, 2026 21:14 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative	25,000	$0.00 Strike: $26.27	$0.00	Disclosure SEC source: 0001193125-26-262067 · ownership.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires 2027-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were granted on January 30, 2017 and are fully vested. Read SEC document
June 04, 2026 Filed Jun 8, 2026 21:14 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionClass A Common Stock	25,000	$26.27	$656,750.00	Disclosure SEC source: 0001193125-26-262067 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000006 · wk-form4_1780430859.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units vested on May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	6,829	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000006 · wk-form4_1780430859.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,257 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 22, 2026 Filed May 27, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Premium) · Derivative	234	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000004 · wk-form4_1779912440.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 22, 2026 Filed May 27, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	1,173	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000004 · wk-form4_1779912440.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 22, 2026 Filed May 27, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	234	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000004 · wk-form4_1779912440.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,428 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 22, 2026 Filed May 27, 2026 20:07 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	1,173	$0.00	$0.00	Disclosure SEC source: 0001250252-26-000004 · wk-form4_1779912440.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,194 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
January 28, 2026 Filed Jan 29, 2026 01:30 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	Disposition to issuerCommon Shares	4,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001250252-26-000002 · form4-01282026_080107.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. F2 · price: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:56 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $94.15	$0.00	Disclosure SEC source: 0001193125-26-021218 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: These options were granted on January 21, 2026, and will vest on January 1, 2027. Read SEC document
December 10, 2025 Filed Dec 10, 2025 23:37 UTC	QuidelOrtho Corp QDEL · Entity 4986	PurchaseCommon Stock	750	$28.28	$21,206.25	Disclosure SEC source: 0001250252-25-000004 · wk-form4_1765409834.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,021 Read SEC document
November 10, 2025 Filed Nov 10, 2025 21:15 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	2,000	$85.00	$170,000.00	Disclosure SEC source: 0001193125-25-274288 · ownership.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,384 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person. Read SEC document
November 07, 2025 Filed Nov 10, 2025 21:15 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	8,000	$81.00	$648,000.00	Disclosure SEC source: 0001193125-25-274288 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,384 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person. Read SEC document
September 15, 2025 Filed Sep 16, 2025 21:16 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	10,000	$58.46	$584,600.00	Disclosure SEC source: 0001193125-25-205135 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,384 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $58.22-$58.81, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document
August 29, 2025 Filed Aug 29, 2025 16:30 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Disposition to issuerStock Option (Right to Buy) · Derivative	27,178	Not disclosed Strike: $6.16	Not disclosed	Disclosure SEC source: 0001193125-25-192817 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,178 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2 · kind: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2 · price: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2 · derivative.exercise_date: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") F2 · derivative.expiration_date: (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:11 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	325	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 325 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:11 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	1,626	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 Underlying: Common Stock · 1,626 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on November 29, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on November 29, 2025. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:11 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document
May 29, 2025 Filed Jun 3, 2025 20:08 UTC Amendment	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	325	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000135 · wk-form4a_1748981286.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 325 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F4 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F4 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document
May 29, 2025 Filed Jun 3, 2025 20:08 UTC Amendment	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Converted) · Derivative	1,626	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000135 · wk-form4a_1748981286.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 Underlying: Common Stock · 1,626 shares Expires not disclosed F3 · security: The Form 4 originally filed on June 2, 2025 is being amended to report the correct vesting dates for the converted restricted stock units granted to the reporting person on May 29, 2025. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F5 · derivative.exercise_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on February 28, 2026. F4 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F5 · derivative.expiration_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on February 28, 2026. Read SEC document
May 29, 2025 Filed Jun 3, 2025 20:08 UTC Amendment	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Equity Grant) · Derivative	6,829	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000135 · wk-form4a_1748981286.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document
May 24, 2025 Filed May 28, 2025 20:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Premium) · Derivative	109	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000110 · wk-form4_1748463542.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 24, 2025 Filed May 28, 2025 20:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	546	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000110 · wk-form4_1748463542.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 24, 2025 Filed May 28, 2025 20:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	109	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000110 · wk-form4_1748463542.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,271 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 24, 2025 Filed May 28, 2025 20:19 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	546	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000110 · wk-form4_1748463542.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,162 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 22, 2025 Filed May 27, 2025 20:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	4,929	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000098 · wk-form4_1748377595.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units vested on May 22, 2025. Read SEC document
May 22, 2025 Filed May 27, 2025 20:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	4,929	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000098 · wk-form4_1748377595.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,616 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 18, 2025 Filed May 20, 2025 21:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Premium ) · Derivative	128	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000077 · wk-form4_1747776359.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 18, 2025 Filed May 20, 2025 21:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000077 · wk-form4_1747776359.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
May 18, 2025 Filed May 20, 2025 21:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	128	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000077 · wk-form4_1747776359.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,687 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 18, 2025 Filed May 20, 2025 21:26 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	427	$0.00	$0.00	Disclosure SEC source: 0001906324-25-000077 · wk-form4_1747776359.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,559 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
February 28, 2025 Filed Mar 4, 2025 21:38 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	7,500	$78.68	$590,100.00	Disclosure SEC source: 0000950170-25-032220 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,384 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person. Read SEC document
January 23, 2025 Filed Mar 28, 2025 22:58 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $92.42	$0.00	Disclosure SEC source: 0000950170-25-047031 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: These options were granted on January 23, 2025, and will vest on January 1, 2026. Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:34 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative	20,000	$0.00 Strike: $25.52	$0.00	Disclosure SEC source: 0000950170-24-107319 · ownership.xml · derivative · entry 5 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,000 shares Expires 2026-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on January 25, 2016 and are fully vested. Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:34 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $24.10	$0.00	Disclosure SEC source: 0000950170-24-107319 · ownership.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,000 shares Expires 2025-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on January 20, 2015 and are fully vested. Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:34 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	15,000	$70.36	$1,055,400.00	Disclosure SEC source: 0000950170-24-107319 · ownership.xml · nonDerivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,884 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:34 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionClass A Common Stock	20,000	$25.52	$510,400.00	Disclosure SEC source: 0000950170-24-107319 · ownership.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 13, 2024 Filed Sep 17, 2024 20:34 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	Exercise / conversionClass A Common Stock	15,000	$24.10	$361,500.00	Disclosure SEC source: 0000950170-24-107319 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:35 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantStock Option (right to buy) · Derivative	27,200	$0.00 Strike: $3.80	$0.00	Disclosure SEC source: 0001415889-24-017659 · form4-06202024_040616.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:00 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	24,200	$0.00 Strike: $16.32	$0.00	Disclosure SEC source: 0000950170-24-073252 · ownership.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,200 Underlying: Common Stock · 24,200 shares Expires 2034-06-11 Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock (Premium) · Derivative	203	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071330 · ownership.xml · derivative · entry 4 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Converted) · Derivative	1,017	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071330 · ownership.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,017 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	203	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071330 · ownership.xml · nonDerivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,132 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	1,017	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071330 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,929 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 24, 2024 Filed May 29, 2024 20:40 UTC	QuidelOrtho Corp QDEL · Entity 4986	Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative	2,416	$0.00	$0.00	Disclosure SEC source: 0000950170-24-066006 · ownership.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 24, 2024. F3 · derivative.expiration_date: The restricted stock units vested on May 24, 2024. Read SEC document
May 24, 2024 Filed May 29, 2024 20:40 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantCommon Stock	2,416	$0.00	$0.00	Disclosure SEC source: 0000950170-24-066006 · ownership.xml · nonDerivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,912 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document
May 22, 2024 Filed May 23, 2024 22:28 UTC	QuidelOrtho Corp QDEL · Entity 4986	GrantRestricted Stock Units (Premium) · Derivative	234	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064144 · ownership.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 Underlying: Common Stock · 234 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 22, 2025. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.